These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1690068)

  • 1. Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy.
    Chow W; Hahn D; Sandhu D; Slaney P; Henshaw R; Das G; Wells P
    Br J Urol; 1990 Jan; 65(1):36-8. PubMed ID: 1690068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoramin--an effective new drug in the management of bladder outflow obstruction.
    Iacovou JW; Dunn M
    Br J Urol; 1987 Dec; 60(6):526-8. PubMed ID: 2447995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoramin in the treatment of prostatic bladder outflow obstruction.
    Stott MA; Abrams P
    Br J Urol; 1991 May; 67(5):499-501. PubMed ID: 1710162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is indoramin an effective alternative to prostatectomy?
    Lloyd SN; McMahon A; Muller W; Buckley JF; Deane RF; Kirk D; Kyle KF
    Br J Urol; 1992 Oct; 70(4):408-11. PubMed ID: 1450850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Roehrborn CG
    Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavoxate treatment of micturition disorders accompanying benign prostatic hypertrophy: a double-blind placebo-controlled multicenter investigation.
    Dahm TL; Ostri P; Kristensen JK; Walter S; Frimodt-Møller C; Rasmussen RB; Nøhr M; Alexander N
    Urol Int; 1995; 55(4):205-8. PubMed ID: 8588267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis?
    O'Riordan JI; Doherty C; Javed M; Brophy D; Hutchinson M; Quinlan D
    J Urol; 1995 Apr; 153(4):1114-6. PubMed ID: 7869476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, double-blind, placebo-controlled trial of the efficacy of prazosin in the treatment of dysuria associated with benign prostatic hypertrophy.
    Le Duc A; Cariou G; Baron C; Cukier J; Quentel P; Faure G; Rambeaud JJ; Navratil H; Costa P; Richaud JJ
    Urol Int; 1990; 45 Suppl 1():56-62. PubMed ID: 1690483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.
    Maria G; Brisinda G; Civello IM; Bentivoglio AR; Sganga G; Albanese A
    Urology; 2003 Aug; 62(2):259-64; discussion 264-5. PubMed ID: 12893330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia.
    Chapple CR; Stott M; Abrams PH; Christmas TJ; Milroy EJ
    Br J Urol; 1992 Sep; 70(3):285-94. PubMed ID: 1384919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy].
    Kumamoto Y; Tsukamoto T; Yachiku S; Kaneko S; Koyanagi T; Togashi M; Maru A; Tsuchida S; Nishizawa O; Orikasa S
    Hinyokika Kiyo; 1990 Oct; 36(10):1213-32. PubMed ID: 1702262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Indoramin, an alpha blocker, in functional disorders of the lower urinary tract].
    García Ortiz R; Jara O; Barbera A
    Rev Med Chil; 1985 Jan; 113(1):12-7. PubMed ID: 4081378
    [No Abstract]   [Full Text] [Related]  

  • 15. Flutamide in treatment of benign prostatic hypertrophy.
    Stone NN
    Urology; 1989 Oct; 34(4 Suppl):64-8; discussion 87-96. PubMed ID: 2477936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
    Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
    Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
    Buzelin JM; Hebert M; Blondin P
    Br J Urol; 1993 Dec; 72(6):922-7. PubMed ID: 7508331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term indoramin therapy in congestive heart failure: a double-blind, randomized, parallel placebo-controlled trial.
    Leier CV; Binkley PF; Randolph PH; Unverferth DV
    J Am Coll Cardiol; 1987 Feb; 9(2):426-32. PubMed ID: 3543093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism].
    Kumamoto Y; Yokoyama E; Tsukamoto T; Tsuchida S; Nishizawa O; Koshiba K; Ishibashi A; Ogawa A; Tomita Y; Aso Y
    Hinyokika Kiyo; 1987 Oct; 33(10):1681-702. PubMed ID: 2451409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia.
    McVary KT; Roehrborn CG; Chartier-Kastler E; Efros M; Bugarin D; Chen R; Patel A; Haag-Molkenteller C
    J Urol; 2014 Jul; 192(1):150-6. PubMed ID: 24508634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.